Related references
Note: Only part of the references are listed.Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials
Philippe Huot et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2022)
A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease
Olivier Rascol et al.
MOVEMENT DISORDERS (2022)
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson's Disease: A Perspective Through Preclinical and Clinical Evidence
Ritam Bandopadhyay et al.
FRONTIERS IN PHARMACOLOGY (2022)
Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019
Zejin Ou et al.
FRONTIERS IN PUBLIC HEALTH (2021)
Amantadine ER (Gocovri(R)) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
Robert A. Hauser et al.
FRONTIERS IN NEUROLOGY (2021)
Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial
Eric Freire-Alvarez et al.
MOVEMENT DISORDERS (2021)
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis
Ahmed Negida et al.
NEUROLOGICAL SCIENCES (2021)
MR-guided focused ultrasound pallidotomy for Parkinson's disease: safety and feasibility
Howard M. Eisenberg et al.
JOURNAL OF NEUROSURGERY (2021)
beta-adrenoreceptors and the risk of Parkinson's disease
Franziska Hopfner et al.
LANCET NEUROLOGY (2020)
Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study
Heinz Reichmann et al.
TRANSLATIONAL NEURODEGENERATION (2020)
The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease
Dirk Woitalla et al.
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE (2020)
An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease
Silvia Cerri et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Cholinergic control of striatal neurons to modulate L-dopa-induced dyskinesias
Tanuja Bordia et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2019)
Circuit Mechanisms of Parkinson's Disease
Matthew M. McGregor et al.
NEURON (2019)
Chronic administration of the histamine H3 receptor agonist immepip decreases l-Dopa-induced dyskinesias in 6-hydroxydopamine-lesioned rats
Alberto Avila-Luna et al.
PSYCHOPHARMACOLOGY (2019)
Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson's disease
Peter A. LeWitt et al.
PARKINSONISM & RELATED DISORDERS (2019)
Rotigotine Transdermal Patch: A Review in Parkinson's Disease
James E. Frampton
CNS DRUGS (2019)
Effects of Muscarinic Acetylcholine m1 and m4 Receptor Blockade on Dyskinesia in the Hemi-Parkinsonian Rat
Nicole E. Chambers et al.
NEUROSCIENCE (2019)
Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson's Rats
Wen-Wen Wang et al.
FRONTIERS IN PHARMACOLOGY (2019)
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease
Fabio Del Bello et al.
BIOMOLECULES (2019)
Design, Synthesis, and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson's Disease
Asma Elmabruk et al.
ACS CHEMICAL NEUROSCIENCE (2019)
The Accordion Pill®: unique oral delivery to enhance pharmacokinetics and therapeutic benefit of challenging drugs
Nadav Navon
THERAPEUTIC DELIVERY (2019)
Efficacy and safety of perampanel in Parkinson's disease. A systematic review with meta-analysis
Simona Lattanzi et al.
JOURNAL OF NEUROLOGY (2018)
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying L-Dopa-induced wearing-off and abnormal involuntary movements
Hiroko Tsunekawa et al.
BEHAVIOURAL BRAIN RESEARCH (2018)
mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia
Irene Sebastianutto et al.
CURRENT OPINION IN PHARMACOLOGY (2018)
Deep brain stimulation for Parkinson's disease: meta-analysis of results of randomized trials at varying lengths of follow-up
Alireza Mansouri et al.
JOURNAL OF NEUROSURGERY (2018)
Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats
Adrian Newman-Tancredi et al.
NEUROCHEMICAL RESEARCH (2018)
Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders
Robert F. Bruns et al.
NEUROPHARMACOLOGY (2018)
Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
Vibhash D. Sharma et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Opioidergic Modulation of Striatal Circuits, Implications in Parkinson's Disease and Levodopa Induced Dyskinesia
Stefania Sgroi et al.
FRONTIERS IN NEUROLOGY (2018)
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced L-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia
Andrew J. Flores et al.
NEUROPHARMACOLOGY (2018)
Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
Libo Wang et al.
FRONTIERS IN NEUROLOGY (2018)
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts
Alberto J. Espay et al.
ANNALS OF NEUROLOGY (2018)
Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated
U. Shivraj Sohur et al.
NEUROLOGY AND THERAPY (2018)
Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial
Per Svenningsson et al.
NPJ PARKINSONS DISEASE (2018)
Recent advances in discovery and development of natural products as source for anti-Parkinson's disease lead compounds
Hongjia Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Trial of Dextromethorphan/Quinidine to Treat Levodopa-Induced Dyskinesia in Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2017)
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias
Jennifer Stanic et al.
NEUROBIOLOGY OF DISEASE (2017)
Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms
Xuefei Huang et al.
ONCOTARGET (2017)
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations A Randomized Clinical Trial
Anthony H. V. Schapira et al.
JAMA NEUROLOGY (2017)
Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease
Marianne Udd et al.
BRAIN AND BEHAVIOR (2017)
Parkinson disease
Werner Poewe et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Nicotine from cigarette smoking and diet and Parkinson disease: a review
Chaoran Ma et al.
TRANSLATIONAL NEURODEGENERATION (2017)
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease
Gennaro Pagano et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2017)
D-512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti-Parkinsonian efficacy than ropinirole in Parkinsonian rats
David Lindenbach et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Safinamide: A Review in Parkinson's Disease
Hannah A. Blair et al.
CNS DRUGS (2017)
Improvement of dyskinesias with l-dopa infusion in advanced Parkinson's disease
J. Timpka et al.
ACTA NEUROLOGICA SCANDINAVICA (2016)
Memantine and reduced time with dyskinesia in Parkinson's Disease
K. Wictorin et al.
ACTA NEUROLOGICA SCANDINAVICA (2016)
Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons
Polina Kosillo et al.
CEREBRAL CORTEX (2016)
Novel Levodopa Formulations for Parkinson's Disease
Maria Eliza Freitas et al.
CNS DRUGS (2016)
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
Dhanya Vijayakumar et al.
DRUGS (2016)
Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study
Hana Florian et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in L-DOPA-Induced Dyskinesia in Parkinsonian Rats
David Lindenbach et al.
JOURNAL OF NEUROSCIENCE (2016)
Movement Disorders A Brief Guide in Medication Management
Anthony Julius et al.
MEDICAL CLINICS OF NORTH AMERICA (2016)
A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease
Peter A. LeWitt et al.
MOVEMENT DISORDERS (2016)
Validation of an improved scale for rating L-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists
Irene Sebastianutto et al.
NEUROBIOLOGY OF DISEASE (2016)
In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease
Sherise L. Simms et al.
NEUROPHARMACOLOGY (2016)
Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model
Mitchell J. Bartlett et al.
NEUROSCIENCE LETTERS (2016)
Practical management of adverse events related to apomorphine therapy
Roongroj Bhidayasiri et al.
PARKINSONISM & RELATED DISORDERS (2016)
Apomorphine - pharmacological properties and clinical trials in Parkinson's disease
Peter Jenner et al.
PARKINSONISM & RELATED DISORDERS (2016)
Dopamine release from the locus coeruleus to the dorsal hippocampus promotes spatial learning and memory
Kimberly A. Kempadoo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats
Xuebing Cao et al.
BIOLOGICAL RESEARCH (2016)
Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L-DOPA-Induced Dyskinesias
Scott J. Sherman et al.
CASE REPORTS IN NEUROLOGY (2016)
Dual -agonist/-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease
Lisa F. Potts et al.
ANNALS OF NEUROLOGY (2015)
Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease
Flavia Niccolini et al.
BRAIN (2015)
Zonisamide Improves Wearing- Off in Parkinson's Disease: A Randomized, Double- Blind Study
Miho Murata et al.
MOVEMENT DISORDERS (2015)
New Treatments for Levodopa-Induced Motor Complications
Olivier Rascol et al.
MOVEMENT DISORDERS (2015)
Nitric oxide synthase inhibition decreases L-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice
Oscar Solis et al.
NEUROBIOLOGY OF DISEASE (2015)
Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease
Manuela Pilleri et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Novel Formulations and Modes of Delivery of Levodopa
Werner Poewe et al.
MOVEMENT DISORDERS (2015)
Presynaptic Effects of Levodopa and Their Possible Role in Dyskinesia
Eugene V. Mosharov et al.
MOVEMENT DISORDERS (2015)
CURRENT TREATMENT AND FUTURE PROSPECTS OF DOPA-INDUCED DYSKINESIAS
S. Mazzucchi et al.
DRUGS OF TODAY (2015)
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa
Roberto Cilia et al.
BRAIN (2014)
Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
Eva Schaeffer et al.
CNS DRUGS (2014)
Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
Annalisa Pinna
CNS DRUGS (2014)
Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson's disease
Sevgi Sayin et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2014)
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
Jeffrey Cummings et al.
LANCET (2014)
Double-Blind Study of the Actively Transported Levodopa Prodrug XP21279 in Parkinson's Disease
Peter A. LeWitt et al.
MOVEMENT DISORDERS (2014)
Combined Fenobam and Amantadine Treatment Promotes Robust Antidyskinetic Effects in the 1-Methyl-4-Phenyl1,2,3,6-Tetrahydropyridine ( MPTP)-Lesioned Primate Model of Parkinson's Disease
Wai Kin D. Ko et al.
MOVEMENT DISORDERS (2014)
Two-Year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson's Disease
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease
Danhui Zhang et al.
MOVEMENT DISORDERS (2014)
Direct and indirect pathways of basal ganglia: a critical reappraisal
Paolo Calabresi et al.
NATURE NEUROSCIENCE (2014)
Effect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis
Cheng-long Xie et al.
NEUROLOGICAL SCIENCES (2014)
Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1-and D2-induced abnormal involuntary movements in a preclinical model
Andrew J. Flores et al.
NEUROSCIENCE LETTERS (2014)
Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease
Christopher Kobylecki et al.
PARKINSONISM & RELATED DISORDERS (2014)
Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias
Olivier Rascol et al.
PARKINSONISM & RELATED DISORDERS (2014)
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats
Cheng-long Xie et al.
SCIENTIFIC REPORTS (2014)
Modulating mGluR5 and 5-HT1A/1B receptors to treat L-DOPA-induced dyskinesia: Effects of combined treatment and possible mechanisms of action
Hanna Iderberg et al.
EXPERIMENTAL NEUROLOGY (2013)
Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations
Thomas Mueller
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Experimental reappraisal of continuous dopaminergic stimulation against L-dopa-induced dyskinesia
Erwan Bezard
MOVEMENT DISORDERS (2013)
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
C. Warren Olanow et al.
MOVEMENT DISORDERS (2013)
Caffeine consumption and risk of dyskinesia in CALM-PD
Anne-Marie A. Wills et al.
MOVEMENT DISORDERS (2013)
Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA
Elzbieta Lorenc-Koci et al.
NEUROCHEMISTRY INTERNATIONAL (2013)
Norepinephrine and impulsivity: effects of acute yohimbine
Alan C. Swann et al.
PSYCHOPHARMACOLOGY (2013)
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats
Christopher Bishop et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2012)
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
Peter A. LeWitt et al.
NEUROLOGY (2012)
GPi and STN deep brain stimulation can suppress dyskinesia in Parkinson's disease
Genko Oyama et al.
PARKINSONISM & RELATED DISORDERS (2012)
Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial
O. Rascol et al.
PARKINSONISM & RELATED DISORDERS (2012)
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
Veronique Sgambato-Faure et al.
PROGRESS IN NEUROBIOLOGY (2012)
Adenosine A2A Receptor Antagonists and Parkinson's Disease
Brian C. Shook et al.
ACS CHEMICAL NEUROSCIENCE (2011)
Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias
Imtiaz Ahmed et al.
BRAIN (2011)
Deletion of adenosine A1 or A2A receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease
Danqing Xiao et al.
BRAIN RESEARCH (2011)
Safety of rasagiline for the treatment of Parkinson's disease
Santiago Perez-Lloret et al.
EXPERT OPINION ON DRUG SAFETY (2011)
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation
Mahmoud M. Iravani et al.
JOURNAL OF NEURAL TRANSMISSION (2011)
L-Dopa activates histaminergic neurons
Yevgenij Yanovsky et al.
JOURNAL OF PHYSIOLOGY-LONDON (2011)
Graft-Induced Dyskinesias in Parkinson's Disease: High Striatal Serotonin/Dopamine Transporter Ratio
Marios Politis et al.
MOVEMENT DISORDERS (2011)
Role of Pramipexole in the Management of Parkinson's Disease
Angelo Antonini et al.
CNS DRUGS (2010)
Entacapone
Thomas Mueller
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia
Hanna S. Lindgren et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Pharmacokinetics of levodopa
Manuela Contin et al.
JOURNAL OF NEUROLOGY (2010)
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
Paolo Calabresi et al.
LANCET NEUROLOGY (2010)
Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease
Elisabeth Wolf et al.
MOVEMENT DISORDERS (2010)
Age of Parkinson's Disease Onset as a Predictor for the Development of Dyskinesia
Stephen Ku et al.
MOVEMENT DISORDERS (2010)
Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson's Patients with Neural Transplants
Marios Politis et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole
Izchak Kohen
Neuropsychiatric Disease and Treatment (2010)
Dopamine Depletion Induces Distinct Compensatory Gene Expression Changes in DARPP-32 Signal Transduction Cascades of Striatonigral and Striatopallidal Neurons
Bernhard H. Meurers et al.
JOURNAL OF NEUROSCIENCE (2009)
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders
Valerie Voon et al.
LANCET NEUROLOGY (2009)
Priming for L-dopa-induced dyskinesia in Parkinson's disease: A feature inherent to the treatment or the disease?
Agnes Nadjar et al.
PROGRESS IN NEUROBIOLOGY (2009)
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders
P. Jeffrey Conn et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces Off' time in Parkinson's disease:: A double-blind, randomized, multicenter clinical trial (6002-US-005)
Peter A. LeWitt et al.
ANNALS OF NEUROLOGY (2008)
Pharmacokinetics and pharmacodynamics of levodopa
John G. Nutt
MOVEMENT DISORDERS (2008)
Molecular mechanisms of L-DOPA-induced dyskinesia
Peter Jenner
NATURE REVIEWS NEUROSCIENCE (2008)
Adenosine and its receptors - Multiple modulatory functions and potential therapeutic targets for neurologic disease
Eduardo E. Benarroch
NEUROLOGY (2008)
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias
Melanie A. Paquette et al.
NEUROREPORT (2008)
Histamine H3 receptor ligands modulate L-DOPA-evoked behavioral responses and L-DOPA-derived extracellular dopamine in dopamine-denervated rat striatum
Przemyslaw Nowak et al.
NEUROTOXICITY RESEARCH (2008)
Muscarinic acetylcholine receptors as CNS drug targets
Christopher J. Langmead et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
Robert A. Hauser et al.
MOVEMENT DISORDERS (2007)
Levodopa-induced dyskinesias
Giovanni Fabbrini et al.
MOVEMENT DISORDERS (2007)
Levodopa-induced dyskinesia in Parkinson's disease: Epidemiology, etiology, and treatment
Theresa A. Zesiewicz et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2007)
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats
Manolo Carta et al.
BRAIN (2007)
The selective κ-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates
Heather Cox et al.
EXPERIMENTAL NEUROLOGY (2007)
Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors
S. Papapetropoulos et al.
JOURNAL OF NEURAL TRANSMISSION (2007)
Sarizotan as a treatment for dyskinesias in Parkinson's disease:: A double-blind placebo-controlled trial
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2007)
Rasagiline - A review of its use in the management of Parkinson's disease
Vicki Oldfield et al.
DRUGS (2007)
ST 1535:: A preferential A2A adenosine receptor antagonist
Maria Antonietta Stasi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2006)
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys:: Effect on adenosine A2A receptors
Marc Morissette et al.
SYNAPSE (2006)
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
C. Warren Olanow et al.
LANCET NEUROLOGY (2006)
Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease
Warren Olanow et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2006)
Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease
Jordi Gomez-Ramirez et al.
MOVEMENT DISORDERS (2006)
Switching from levodopa to the long-acting dopamine D2/D3 agonist Piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates
Lance A. Smith et al.
CLINICAL NEUROPHARMACOLOGY (2006)
Competition between feedback loops underlies normal and pathological dynamics in the basal ganglia
A Leblois et al.
JOURNAL OF NEUROSCIENCE (2006)
Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade)
Jagdish C. Sharma et al.
PARKINSONISM & RELATED DISORDERS (2006)
Function of sigma1 receptors in Parkinson's disease
M Mishina et al.
ACTA NEUROLOGICA SCANDINAVICA (2005)
Pathogenesis of levodopa-induced dyskinesia:: focus on D1 and D3 dopamine receptors
C Guigoni et al.
PARKINSONISM & RELATED DISORDERS (2005)
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease -: An exploratory study
M Zappia et al.
ARCHIVES OF NEUROLOGY (2005)
Continuous subcutaneous apomorphine therapy improves Dyskinesias in Parkinson's disease: A prospective study using single-dose challenges
R Katzenschlager et al.
MOVEMENT DISORDERS (2005)
Clozapine improves dyskinesias in Parkinson disease - A double-blind, placebo-controlled study
F Durif et al.
NEUROLOGY (2004)
Subthalamic nucleus deep brain stimulation for Parkinson's disease after successful pallidotomy: Clinical and electrophysiological observations
G Kleiner-Fisman et al.
MOVEMENT DISORDERS (2004)
Myoclonus: current concepts and recent advances
JN Caviness et al.
LANCET NEUROLOGY (2004)
Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis
L Morgante et al.
CLINICAL NEUROPHARMACOLOGY (2004)
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
C Konradi et al.
NEUROBIOLOGY OF DISEASE (2004)
Adenosine A2A receptor antagonist treatment of Parkinson's disease
W Bara-Jimenez et al.
NEUROLOGY (2003)
Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
JM Savola et al.
MOVEMENT DISORDERS (2003)
Mirtazapine in L-dopa-induced dyskinesias
G Meco et al.
CLINICAL NEUROPHARMACOLOGY (2003)
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
E Bézard et al.
NATURE MEDICINE (2003)
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6-OHDA-lesioned rat
JE Nash et al.
MOVEMENT DISORDERS (2002)
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)
WH Poewe et al.
ACTA NEUROLOGICA SCANDINAVICA (2002)
μ- and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
B Henry et al.
EXPERIMENTAL NEUROLOGY (2001)
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
E Bezard et al.
NATURE REVIEWS NEUROSCIENCE (2001)
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
O Rascol et al.
MOVEMENT DISORDERS (2001)
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
JE Ahlskog et al.
MOVEMENT DISORDERS (2001)
Mecamylamine: New therapeutic uses and toxicity/risk profile
JM Young et al.
CLINICAL THERAPEUTICS (2001)
Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of L-DOPA-induced dyskinesia
PA Johansson et al.
NEUROBIOLOGY OF DISEASE (2001)
Pathophysiology of the basal ganglia in Parkinson's disease
JA Obeso et al.
TRENDS IN NEUROSCIENCES (2000)
Continuous dopamine-receptor stimulation in advanced Parkinson's disease
JG Nutt et al.
TRENDS IN NEUROSCIENCES (2000)
Synaptic transmission in the striatum: from plasticity to neurodegeneration
P Calabresi et al.
PROGRESS IN NEUROBIOLOGY (2000)
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA
BY Zeng et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2000)
The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study
BJ Snow et al.
CLINICAL NEUROPHARMACOLOGY (2000)
Share Paper
